There is a particular kind of organization that everyone in an industry has heard of and almost no one outside it can describe. The Biotechnology Innovation Organization - BIO, to the people who deal with it - is one of these. It is a trade association, which is a polite way of saying it is a machine for turning the shared interests of a thousand companies into something a member of Congress will actually read. That the thousand companies frequently disagree with each other is not a bug. It is the entire job.
Start with what BIO is not. It is not a company that makes a drug, or a crop, or a fuel. It does not run clinical trials or file for FDA approval. It has no product in the sense that a biotech has a product. What it has is roughly a thousand members - startups with two employees, pharmaceutical companies with tens of thousands, universities, state biotech centers, and the odd venture fund - and a mandate to speak for all of them at once, in Washington and in more than thirty other countries.
This is harder than it sounds, because the interests of a two-person startup and a multinational pharma company are not the same interests. The startup wants patents to be strong and capital to be cheap. The giant wants the same things, mostly, until a policy fight arrives where "mostly" stops being good enough. BIO's real product, the thing it actually sells to its members through their dues, is the maintenance of a coalition that has every structural reason to splinter and mostly doesn't.
The organization was assembled in 1993 out of two smaller groups - the Industrial Biotechnology Association and the Association of Biotechnology Companies - on the theory that one large voice beats two medium ones. Carl Feldbaum ran it for the first decade. The name you see today arrived in 2016, when "Biotechnology Industry Organization" became "Biotechnology Innovation Organization," a change that preserved the acronym and the letterhead budget while gently repositioning the whole thing from a lobby that defends an industry to a movement that champions innovation. Whether those are different things is a question the industry would prefer you not think about too hard.
What BIO does all day is advocacy, which in practice means several jobs stacked on top of each other. It lobbies - on drug pricing, on intellectual property, on how the FDA reviews therapies, on biosecurity, on the rules governing genetically modified crops and biofuels. It convenes, most visibly through the BIO International Convention, the industry's flagship event. And it communicates, running a steady stream of briefings and news that keep members and policymakers pointed in roughly the same direction.
"BIO's mission is to be the champion of biotechnology and the advocate for its member organizations - both large and small."
— BIO's stated mission
The drug-pricing problem, stated plainly
Here is the tension BIO lives inside, and it is worth stating without spin. Everybody wants two things that are difficult to have simultaneously: cheaper medicines and more new medicines. Cheaper medicines are good, obviously. New medicines require someone to spend a decade and a fortune on a molecule that usually fails, which they will only do if the ones that work can be sold at a price that pays for all the failures. Push the price down and you get relief today; push it too far and you get fewer cures tomorrow. There is no clever framing that makes this go away. It is just a tradeoff, and someone in Washington has to argue the expensive side of it.
That someone is frequently BIO. When the federal government moved to negotiate Medicare drug prices and later revived "most-favored-nation" pricing - the idea that Americans shouldn't pay more than patients abroad - BIO's members were the ones most exposed, and BIO's argument was the predictable one: that squeezing prices squeezes the money that funds the next generation of therapies. You do not have to find this argument fully convincing to notice that it is not obviously wrong, which is exactly what makes the fight durable.
Fig. 1 — What "biotechnology" actually covers (share of BIO's advocacy footprint, illustrative)
Industrial / enzymes
growing
A useful reminder: when people say "biotech" they usually mean medicine, but BIO also speaks for the companies engineering crops, enzymes and fuels. The category is wider than the headlines.
The man who runs it took the job the hard way
In March 2024, BIO got a new President and CEO: John F. Crowley. His résumé is the kind that sounds invented. In 1998, two of his young children were diagnosed with Pompe disease, a rare and often fatal neuromuscular disorder for which there was no treatment. Crowley, then working at Bristol Myers Squibb, did the thing people say they would do and almost never do - he left, co-founded a biotech to chase a treatment, and eventually built a career in rare disease that ran through the company Amicus Therapeutics, which he led for the better part of two decades. The story was dramatic enough that Hollywood made a film loosely based on it, with Brendan Fraser standing in for the desperate father.
The interesting thing about hiring Crowley is what it signals. A trade association could pick a career lobbyist or a former congressman - BIO has done both. Instead it picked a patient advocate who happens to have run a public biotech, which is a way of saying: we would like the industry's public face to be the reason the industry exists rather than the mechanics of how it operates. Whether that survives contact with a drug-pricing negotiation is a separate question. Early on, Crowley moved fast - a wide restructuring inside his first hundred days and a notably firm posture toward Congress on biosecurity, the tangle of policy around keeping American biotech research and manufacturing out of adversarial supply chains.
The Convention, In One Paragraph
Speed-dating for an entire industry
Once a year BIO throws the BIO International Convention, and roughly 20,000 people from 70-plus countries show up. Underneath the keynotes and pavilions runs the part that actually moves money: BIO One-on-One Partnering, a matchmaking system that schedules tens of thousands of short meetings between startups, investors and pharma. It is, functionally, speed-dating for billion-dollar partnerships. The 2026 edition runs June 22-25 in San Diego, with 125+ sessions spanning business development, AI and digital health, patient advocacy and public policy.
What you can actually do with BIO
If you are inside the industry, BIO is a set of concrete things. It is the venue where you find a partner or an investor without cold-emailing four hundred strangers. It is the lobby that argues your policy case in rooms you can't get into. It is the network that connects your startup to a state biotech association, a heritage award, a diversity program, a briefing that tells you what just happened in Congress before your competitors figure it out. Membership is the price of admission to a coalition, and the coalition is the point.
If you are outside the industry - a policymaker, a journalist, a curious observer - BIO is something else: a single address for an industry that would otherwise be a thousand scattered voices. That is genuinely useful and also worth watching with clear eyes. A trade association's job is to advance its members' interests, and it is very good at making those interests sound like everyone's interests. Both things can be true at once. Most of Washington runs on exactly this ambiguity.
The File — Biotechnology Innovation Organization
- Founded — 1993 (merger of IBA and ABC)
- Headquarters — Washington, D.C.
- Type — Nonprofit trade association (501(c)(6))
- President & CEO — John F. Crowley (since March 2024)
- Members — 1,000+ organizations, 50 states, 30+ countries
- Signature event — BIO International Convention (2026: San Diego, June 22-25)
- Annual revenue — ~$103M (approximate)
- Prior name — Biotechnology Industry Organization (until 2016)
A coalition under pressure
Coalitions are only interesting when they strain, and BIO's strained a bit recently. In early 2026, roughly a dozen mid-sized biotech companies formed their own group - the Midsized Biotech Alliance of America - on the logic that their interests weren't quite the startups BIO is often built around, nor the pharma giants they'd rather not be lumped with. This is the normal physics of trade associations: as members diverge, sub-coalitions form, and the big tent has to work harder to stay a tent. It is not a crisis. It is a Tuesday. But it is a reminder that "speaking for the industry" is a claim that must be re-earned every year against the centrifugal pull of a thousand members who each think their own case is the important one.
Which brings us back to the beginning. A lobby is just a coalition that hasn't fallen apart yet, and thirty-plus years in, BIO hasn't. That is not nothing. In an industry defined by the failure rate of its science - most drugs never make it, most startups never scale - the association that holds the whole quarrelsome thing together has quietly become one of its more durable products. It doesn't cure anything. It just makes sure the people who might get a slightly better hearing.
The three-word mission, examined
CurePatients
Medicine is the core - drugs, vaccines, gene and cell therapies, rare disease. It's where most of the money, most of the lobbying, and most of the emotional weight of the mission actually sit.
ProtectThe Climate
Industrial and environmental biotech - enzymes, biomanufacturing, biofuels - is the quieter half of the story, the part that turns biology into cleaner materials and energy.
NourishHumanity
Agricultural biotech - engineered crops, food security - is the oldest culture-war front BIO fights on, and the reason "GMO" is still a loaded three letters in public.
